Augustine Therapeutics is a Belgium-based biotech startup that focuses on developing innovative therapies for complex neurological disorders, particularly those associated with axonal dysfunction. The company's primary target is Charcot-Marie-Tooth (CMT), a rare hereditary disorder, and Chemotherapy-Induced Peripheral Neuropathy (CIPN), a condition caused by chemotherapy. Augustine Therapeutics aims to advance the understanding of axonal protection, regeneration, and remyelination, and translate this knowledge into effective treatments for patients with unmet medical needs.

The company's business model revolves around the development of novel therapeutics that can achieve reinnervation, with the goal of slowing down or even reversing the disease. This could provide significant relief for patients affected by axonopathies, a group of diseases characterized by the degeneration of nerve axons. Augustine Therapeutics' assets also have potential applications in other complex neurological disorders.

Currently, the company has three programs in development. The first program is advancing into preclinical development and targets peripherally restricted and selective HDAC6i for CMT and CIPN. The second program, focusing on brain penetrant and selective HDAC6i, is advancing into lead optimization. The third program, targeting subtype-selective GABABR1A activators for CMT1, is at the discovery stage.

Founded in 2019, Augustine Therapeutics is rooted in the groundbreaking research of the VIB laboratory of Ludo Van Den Bosch and the collaboration between the VIB labs of Joris de Wit and Bart De Strooper. The company operates in the biotech market, serving patients suffering from severe peripheral nerve disorders.

Keywords: Biotech, Neurological Disorders, Axonal Dysfunction, Charcot-Marie-Tooth (CMT), Chemotherapy-Induced Peripheral Neuropathy (CIPN), Axonal Protection, Reinnervation, Therapeutics Development, Peripheral Nerve Disorders, HDAC6i.